PMC:7319919 / 2994-3386
Annnotations
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T32 | 87-88 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T22 | 195-203 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T23 | 254-263 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T24 | 321-325 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 98 | 136-139 | Chemical | denotes | HCQ | MESH:D006886 |
| 99 | 144-149 | Chemical | denotes | LPV/r | MESH:C558899 |
| 100 | 195-203 | Chemical | denotes | imatinib | MESH:D000068877 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T31 | 0-392 | Sentence | denotes | These clinical changes suggested that the disease was progressing to an early phase of a hyperinflammatory state despite treatment with HCQ and LPV/r; thus, after assessing the safety profile of imatinib [3] and reviewing previous publications about its antiviral and immunomodulatory properties, we considered that this drug may have potentially beneficial effects in such clinical scenario. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T38 | 195-203 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T39 | 321-325 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T67666 | 195-203 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T83555 | 321-325 | CHEBI:23888;CHEBI:23888 | denotes | drug |